In a significant step forward for the fight against pancreatic cancer, a new, “off-the-shelf” vaccine has shown promising results in a recent clinical trial, igniting hope for a disease with a historically low survival rate. Hackensack University Medical Center’s Pancreas Center is highlighting the breakthrough, which could change the landscape of treatment for patients facing recurrence.
The findings, published in the journal Nature Medicine, focus on a vaccine that stimulates the immune system to target a specific genetic mutation known as KRAS. This mutation is a major driver in a quarter of all cancers and is present in a staggering 90% of pancreatic cancers, making it a difficult and often “undruggable” target for traditional therapies.
Dr. Rosario Ligresti, director of the Pancreas Center at Hackensack University Medical Center, commented on the significance of the study.
“Mutations in k-ras, an important protein in the development of pancreatic cancer, have historically been thought to be undruggable,” Ligresti said. “This study is among the first successful uses of a vaccine to unleash the immune system to potentially block the deleterious effects of k-ras mutations! This hopefully will translate into increased survival in this deadly disease.”
The Phase 1 trial involved 25 patients, 20 with pancreatic cancer and five with colorectal cancer, who had undergone both chemotherapy and surgery but still had residual cancer DNA in their blood, a signal of potential relapse. The vaccine works by using peptides to activate an immune response in the lymph nodes, training the body’s immune cells to recognize and attack cells with the KRAS mutation.
Key findings from the trial include:
- A strong immune response was generated in 21 of the 25 patients.
- In four patients, the biomarkers associated with the tumor were completely cleared.
Unlike many other cancer vaccines that are personalized to a patient’s unique genetic makeup, this new vaccine is a one-size-fits-all approach. This standardized design could make it more widely accessible and easier to distribute, a crucial factor in bringing new treatments to patients faster.
Ligresti, whose center is a part of Hackensack University Medical Center—a top 20 hospital in the nation—knows the implications of this trial, the current state of pancreatic cancer treatment and the importance of early detection. He emphasized the challenge of diagnosis, noting the disease’s asymptomatic nature in its early stages. He advises people to be vigilant for symptoms such as jaundice (yellowing of the skin and eyes), abdominal or back pain, unexplained weight loss, changes in stool and exhaustion.
This research represents a new frontier in cancer therapy, harnessing the body’s own defense system to fight one of the most aggressive forms of the disease. While this is an early-stage trial, the results offer a new beacon of hope for patients and the medical community.
